Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection
| Authors | |
|---|---|
| Year of publication | 2021 |
| MU Faculty or unit | |
| Web | COVID-19 |
| Description | This document reports the first interim pooled estimates from the ECDC study of COVID-19 vaccine effectiveness (VE), conducted through the implementation of a multi-country approach using the Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratoryconfirmed with SARS-CoV-2, version 1.0 [1].Interim pooled estimates of COVID-19 VE were calculated for all COVID-19 vaccines deployed, including the COVID-19 mRNA vaccine Comirnaty (Pfizer/BioNTech), among hospitalised individuals aged 65 years and older with SARI due to laboratory-confirmed SARS-CoV-2, across EU/EEA participating countries. The study is currently ongoing and interim analyses will be conducted on a regular basis, with results updated as relevant. Pooled estimates are from patients recruited across several hospital study sites in the EU/EEA. These interim estimates mainly cover the pre-Delta period, adding further evidence to the existing literature on COVID-19 VE during this time. While VE estimates are important to inform vaccine recommendations, it is also important to ensure that robust methods were used to produce these estimates. Hence, this document presents a detailed description of both the methods used and the characteristics of the cases and controls enrolled in the study. For more details regarding the methods of the study, reference should be made to the core ECDC protocol [1]. |